评估STK17B作为癌症免疫疗法的点,使用高强度和选择性小分子抑制剂
Felix Scheuplein1, Florian Renner2, John E Campbell1
1Blueprint Medicines Corporation, Cambridge, MA, United States.
Frontiers in immunology
|November 6, 2024
概括
研究人员开发了STK17B激酶抑制剂,以增强癌症免疫治疗的T细胞激活. 这些抑制剂促进了T细胞的反应,并在临床前模型中改善了抗PD-L1的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 氨酸/氨酸激酶17B (STK17B) 调节T细胞激活值.
- 缺少STK17B会使T细胞对弱刺激敏感,这表明它有可能成为癌症免疫治疗的目标.
研究的目的:
- 开发用于免疫瘤学的强效和选择性STK17B抑制剂.
- 评估STK17B抑制作为增强抗瘤免疫力的策略.
主要方法:
- 利用一种激酶抑制剂库来识别STK17B工具化合物.
- 已建立的STK17A和STK17B的酶和细胞测试.
- 采用蛋白组学来识别STK17B基质,并开发了基于流细胞计的药理动力学试验.
主要成果:
- STK17B 抑制剂增强了小鼠和人类 T 细胞的 IL-2 生产.
- 确定了BLU7482,一种选择性,口服生物可用的STK17B抑制剂.
- 证明了STK17B活动的剂量依赖的体内调节和增强的T细胞原始化.
- 在临床前瘤模型中,STK17B抑制增加了抗PD-L1抗体的有效性.
结论:
- 成功开发出STK17B激酶抑制剂,可以增加T细胞的反应in vitro和in vivo.
- 验证的STK17B抑制作为癌症免疫治疗的有希望的方法.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Vaccines
341
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
341


